BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38564630)

  • 21. The value of serum Cyfra21-1 as a biomarker in the diagnosis of patients with non-small cell lung cancer: a meta-analysis.
    Cui C; Sun X; Zhang J; Han D; Gu J
    J Cancer Res Ther; 2014 Nov; 10 Suppl():C131-4. PubMed ID: 25450270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overexpression of gene DEP domain containing 1 and its clinical prognostic significance in colorectal cancer.
    Shen X; Han J
    J Clin Lab Anal; 2020 Dec; 34(12):e23634. PubMed ID: 33140894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exosomal miR-338-3p suppresses non-small-cell lung cancer cells metastasis by inhibiting CHL1 through the MAPK signaling pathway.
    Tian W; Yang X; Yang H; Lv M; Sun X; Zhou B
    Cell Death Dis; 2021 Oct; 12(11):1030. PubMed ID: 34718336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dysregulated
    Sui J; Zhao Q; Zhang Y; Liang G
    DNA Cell Biol; 2022 Mar; 41(3):319-329. PubMed ID: 35244469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical value of miR-198-5p in lung squamous cell carcinoma assessed using microarray and RT-qPCR.
    Liang YY; Huang JC; Tang RX; Chen WJ; Chen P; Cen WL; Shi K; Gao L; Gao X; Liu AG; Peng XT; Chen G; Huang SN; Fang YY; Gu YY
    World J Surg Oncol; 2018 Feb; 16(1):22. PubMed ID: 29394946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DYNC1H1 regulates NSCLC cell growth and metastasis by IFN-γ-JAK-STAT signaling and is associated with an aberrant immune response.
    Pan H; Chai W; Liu X; Yu T; Sun L; Yan M
    Exp Cell Res; 2021 Dec; 409(1):112897. PubMed ID: 34717919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DEPDC1 promotes cell proliferation and tumor growth via activation of E2F signaling in prostate cancer.
    Huang L; Chen K; Cai ZP; Chen FC; Shen HY; Zhao WH; Yang SJ; Chen XB; Tang GX; Lin X
    Biochem Biophys Res Commun; 2017 Aug; 490(3):707-712. PubMed ID: 28634077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigation of LINC00342 as a poor prognostic biomarker for human patients with non-small cell lung cancer.
    Tang H; Zhao L; Li M; Li T; Hao Y
    J Cell Biochem; 2019 Apr; 120(4):5055-5061. PubMed ID: 30320899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive value of immediate early response 5 like (IER5L) in the prognosis and immune checkpoint blockade therapy of non-small cell lung cancer patients.
    Wang N; Tan X; Cao S; Liu M
    Pathol Res Pract; 2024 Apr; 256():155270. PubMed ID: 38552564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Using biological information to analyze potential miRNA-mRNA regulatory networks in the plasma of patients with non-small cell lung cancer.
    Zhang W; Zhang Q; Che L; Xie Z; Cai X; Gong L; Li Z; Liu D; Liu S
    BMC Cancer; 2022 Mar; 22(1):299. PubMed ID: 35313857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive analyses of the heterogeneity and prognostic significance of tumor-infiltrating immune cells in non-small-cell lung cancer: Development and validation of an individualized prognostic model.
    Pang Z; Chen X; Wang Y; Wang Y; Yan T; Wan J; Du J
    Int Immunopharmacol; 2020 Sep; 86():106744. PubMed ID: 32623229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrated analysis of the prognostic value of TP53 dependent etoposide-induced gene 24 in non-small cell lung cancer.
    Wang M; Li P; Wan R; Liu X
    Biomed Pharmacother; 2019 Apr; 112():108590. PubMed ID: 30784913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ANKRD29, as a new prognostic and immunological biomarker of non-small cell lung cancer, inhibits cell growth and migration by regulating MAPK signaling pathway.
    Zhao H; Wang Y; He Y; Zhang P; Zeng C; Du T; Shen Q; Zhao S
    Biol Direct; 2023 Jun; 18(1):28. PubMed ID: 37277814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
    BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of the long non-coding RNA LINC01614 in non-small cell lung cancer.
    Sun Y; Ling C
    Medicine (Baltimore); 2019 Jul; 98(30):e16437. PubMed ID: 31348244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meta-analysis of diagnostic and prognostic value of miR-126 in non-small cell lung cancer.
    Sun L; Zhou H; Yang Y; Chen J; Wang Y; She M; Li C
    Biosci Rep; 2020 May; 40(5):. PubMed ID: 32329507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The diagnostic performance of lysine(K)-specific demethylase 6B (
    Ge T; Zhou Y; Lu H
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):2155-2160. PubMed ID: 31155967
    [No Abstract]   [Full Text] [Related]  

  • 38. Low plasma miR-25 expression is a favorite prognosis factor in non-small cell lung cancer.
    Zhang YL; Zhang ZL; Zhu XB; Xu L; Lu P; Xu M; Liu WJ; Zhang XY; Yao HM; Ye XW
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5251-5259. PubMed ID: 31298376
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic role of Wnt pathway gene promoter methylation in non small cell lung cancer.
    Liu S; Chen X; Chen R; Wang J; Zhu G; Jiang J; Wang H; Duan S; Huang J
    Oncotarget; 2017 May; 8(22):36354-36367. PubMed ID: 28422739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA-122-5p promotes the development of non-small cell lung cancer via downregulating p53 and activating PI3K-AKT pathway.
    Fan X; Wu X
    J BUON; 2019; 24(1):273-279. PubMed ID: 30941980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.